





Migrant Health


Underserved population whose health is challenged by...

- -Migratory lifestyle
- -Cultural and language barriers
- -Immigration status
- –Inherent dangers and health risks of occupation
- Lack of access to insurance or financial resources
- -Lack of regulatory protection

© earldotter.com







How do you manage chronic illness with a patient who is on the move?

Questions that lead to solutions.....

How long do you think you are going to be in the area?

Is there any reason you would leave this area?



- Prioritize
 preventive/chronic
 care interventions
- Culturally competent evaluation
- Team approach






Identify possible barriers (today and tomorrow) to achieving the patient's goals.




- Education! Education! Education!
- Self management! Self management!
- Continuity of Care

A lot in a short period of time

The patient in my office today was living in Central America last month. What do I need to know about infectious diseases?





Chagas' Disease


- 8-11 million people infected
- ~50,000 deaths per year
- In 2011 >300,000 people in the US are infected
- ~100,000 will progress to chronic disease*

*Nature 465,S6-S7(24 June 2010)



Trypanosoma Cruzi,

- Reduviids found from southern USA to Argentina, but distribution is erratic
- Humans are not necessary to life cycle
- 150 species of mammals are infected
- Transmission around tree trunks, hollow trees and burrows to non-human mammals
- Disease in humans limited to areas where reduviid can adapt to primitive human dwelling









Case Report Virginia 2012

- Bolivan mother, + Chagas
- Infant by C-sec; 29 wks; fetal Hydrops; ascites,pleural effusion and pericardial effusion
- Peripheral blood pos. *T. cruzi*
- 1st Documented case of Congenital Chagas in US!!!
- Estimated annually 65-315
- 1-10% of children born to infected mothers
- Rx: Infected newborns often asymptomatic (60-90%)
- 60 days benznidazol
- Age 10 months test of cure

(MMWR/Vol.61/No.26 July 6,2012)

Chagas' Disease Acute Phase

- 2 successive phases, acute and chronic.
- Acute phase = 6-8 weeks.
- Acute phase often in childhood, 10-20% mild febrile syndrome (mean age—4; 85% by age 10)
- <u>Chagoma</u>—seen in 50% during acute phase





Chagas' Disease Acute Phase

- Other Symptoms—fever, tachycardia, fatigue, anemia, weakness, hepatosplenomegaly, and lymphadenopathy—myocarditis and meningoencephalitis are rare and have very poor outcomes.
- Most pts. experience spontaneous remission of symptoms, followed by lifelong low-grade parasitemia.

Chagas' Disease Chronic Phase

- 20% to 35% of the infected individuals will develop irreversible lesions of the autonomic nervous system in the heart, esophagus, colon and the peripheral nervous system (~ 100,000 in the US)
- Mean age of onset of chronic disease is 35-45 years old



Chagas' Disease Chronic Phase

- Visceromegaly the heart most often infected—CHF (often R-sided), dysrhythmias, emboli and cardiomyopathy
- #1 cause of cardiac lesions in young, productive adults in endemic regions in Latin America.

Think Chagas in Young Migrants with CHF

Chagas' Disease Chronic Phase

- Megaesophagus, like achalasia, regurg, dysphagia, chronic cough, recurrent aspiration, wt. loss, and increased esophageal cancer
- Megacolon leads to chronic constipation, abd. Pain (obstruction, perforation, sepsis, death)

Think Chagas in Migrants with GI Mega-GI

Chagas Treatment

Unsatisfactory

- Nifurtimox and Benznidazole
- Nifurtimox only available in USA through CDC, not FDA approved
- Severe side effects-GI (nausea/ vomiting, anorexia, abd. Pain, wt. loss); Neurologic (disorientation, insomnia, paresthesias, seizures and polyneuritis)



© PBS

 Reduces the severity and duration of illness and decreases mortality (if patients complete a 60 day course at correct dose up to 80% cure*)

*Nature **465,**S4-S5(24 June 2010)

Chagas' Disease Treatment

- Benznidazole—efficacy similar to Nifurtimox
- Only available in USA through CDC
- Side effects: granulocytopenia, peripheral neuropathy, rash
- Recommended duration—60 days
- BENznidazole Evaluation For Interrupting Trypanosomaiasis (BENEFIT) trial. Started 2004 in Argentina, Brazil and Columbia—3,000 patients. Results reported late 2010 or early 2011*

*Nature 465,S4-S5(24 June 2010)


29


Chagas Treatment

- Supportive Rx for myocarditis, meningoencephalitis, CHF, dysrhythmias; pacemaker may be helpful in bradyarrhythmias
- Rx megaesophagus-dietary changes, dilation of esophagogastric junction
- Megacolon-high fiber diet, laxatives, enemas, later partial resection

Prevention is most important method of treatment

- Identify endemic areas and institute insect eradication program
- Improve housing by eliminating "thatched roofs/stick walls" housing
- Pyrethroid-impregnated bednets





Dengue Fever

- Transmitted by mosquitoes (Aedes aegypti)
- Most patients—mild dis. Flu-like symptoms; severe HA; aching joints/muscles "bonebreak" dis;
- 500,000/yr dengue hemorrhagic fever (capillary leak syndrome—thrombocytopenia; abnormalities in coagulation/LFTs/potentially resulting in shock, bleeding, and organ failure). Almost exclusively in previously infected patients because of "antibodydependent enhancement".

Dengue

 Since 1980 a few locally acquired U.S. cases Texas/Mexico border




- September 2009 first case of dengue Key West, Florida, by April 2010, 28 total cases*
- Key West serosurvey revealed 5.4% residents with recent infection*
- Treatment; symptomatic and supportive only

*MMWR; Vol. 59/No. 19; May 21, 2010

Dengue

- Prevention is still best "treatment"
 - Eliminate mosquito breeding sites
 - Pyrethroidimpregnated Bed nets
 - Personal mosquito repellants




Dengue

- New Modalities to Cut Dengue risk!!
 - Adaption of Wolbachia, a bacterial parasite, mosquito life span reduced to 21 days
 - 2 weeks for mosquitoes newly infected by dengue virus to be able to transmit the infection_
 - When Wolbachia transmitted to offspring they fail to reproduce offspring*


*JAMA, Feb. 18, 2009—Vol. 301 No. 7

Wolbachia infected insect cell



Important Issues Regarding HIV/AIDs in a Migrant Population

- Continuity of Care!
- Migrants coming from regions with different sexual mores- able to engage in new behaviors with fewer restrictions but they can be naive and open to risk. or they may have to engage in survival sex which also has tremendous risk





Hepatitis


- Hep B- sexually transmitted disease same risks as HIV
- Hep C this is actually the most common infectious disease- more so than HIV. while sexual contact is a risk factor the greater risk is blood exchange through needle sharing. rudimentary tattooing in friend groups or social networks is a frequent activity and a concern.


"Tuberculosis is a social problem with a medical aspect"


Sir William Osler, 1904












Global Burden of TB, 2010


WHO Global TB Report, 2011

	Estimated Number of Cases	Estimated Number of Deaths
All forms of TB	9.4 million	1.7 million*
HIV-Associated TB	1.1 million (12%)	380,000
Multidrug-resistant TB (MDR-TB)	440,000	~150,000


Approx. 1/3 of the world (2 billion people) is infected with M.tb

*including deaths among PLHIV






Emergence of "Worst-Case" TB
Scenarios




Drug-Resistant TB

- Drug-resistant TB transmitted the same way as drug-susceptible TB
- Drug resistance is divided into two types:
 - Primary resistance develops in persons initially infected with resistant organisms
 - Secondary resistance (acquired resistance) develops during TB therapy



Why does TB infect one-third of the world's population and still remains global hearth threat despite the fact that highly corpeffective drugs are available to eradicate it?







Addressing the increasing difference between TB rates in foreign-born and US-born persons is critical for TB elimination," CDC said. At the current rate, it would take until 2100 for the United States to eliminate TB, which is defined as less than one case per 1 million people, CDC noted




Evaluation for TB

- Medical history
- Physical examination
- Mantous tuberculin skin test/IGRA
- Chest radiograph
- Bacteriologic or histologic exam

History and Physical Exam








Medical History


- Symptoms of disease
- History of TB exposure, infection or disease
- Past TB treatment
- Demographic risk factors for TB
- Medical conditions that increase risk for TB disease



- Abnormalities
 often seen in
 apical or posterior
 segments of upper
 lobe or superior
 segments of lower
 lobe
- May have unusual appearance in HIVpositive persons
- Cannot confirm diagnosis of TB


- Obtain 3 sputum specimens for smear examination and culture
- Persons unable to cough up sputum, induce sputum, bronchoscopy or gastric aspiration
- Follow infection control precautions during specimen collection






Cultures

- Used to confirm diagnosis of TB
- Culture all specimens, even if smear negative
- Results in 4-14 days when liquid medium used






Drug Regimen for Treatment of LTBI

Drugs	Duration (months)	Interval	Minimum doses
Isoniazid	9	Daily Twice weekly	27076
Isoniazid	6	Daily Twice weekly	180 52
Rifampin	4	Daily	120
INH/Rifapentine	3	Once a week	12

INH Hepatotoxicity

10-20%	Elevations of AST up to 5X normal
0.6%	Clinical Hepatitis (maybe less-in one study it was only 0.1%
2.7%	INH plus RIF
2%	Persons 50-64 years of age

INH hepatotoxicity is increased with liver disease/ alcoholism/postpartum-especially Hispanic women





- Non-adherence is a major problem
- Use case management and Directly Observed Therapy (DOT) to ensure patients complete treatment

Treat of TB for HIV-Negative Persons

 $4 \ \mathsf{drugs} \ \mathsf{in} \ \mathsf{initial} \ 8 \ \mathsf{week} \ \mathsf{regimen}$









- Adjust regimen when drug susceptibility results are known
- Usually INH-RIF in continuation phase (18 weeks)
- Total treatment = 26 weeks




- Management of HIV-related TB is complex
- Care for HIV-related TB should be provided by or in consultation with experts in management of both HIV and TB



Recommendations for BCG Vaccination

- Not recommended in immunization programs or TB control programs in the U.S.
- BCG utilized extensively in most developing countries including Honduras
- BCG <u>only</u> prevents TB Meningitis in infants
- History of BCG immunization <u>is not a</u>
 <u>contraindication</u> for PPD skin testing—test is
 to be read the same

We have a big problem!








New Diagnostic Test for TB



- Xpert MTB/RIF New diagnostic test for TB
 - Automated Rapid Molecular Detection of TB and Rifampin resistance
 - From fresh sputum specimen-> diagnosing TB and detecting resistance to rifampin in less than 2 HOURS!!
 - "Could revolutionize TB care"
 Mario Raviglione WHO STOP TB
 Director





Class 3 Active TB: TBNet Treatment Success (2005-2011)

- √ 1,145 Class 3 Active TB Cases Referred
 - 34 treatment not recommended by destination country
- √ 1,111 Treatment Recommended
 - 13 deceased
- ✓ 1,098 Followed by TBNet for Active TB
 - 112 lost to follow up
 - 64 refused treatment

922 Complete Treatment = 84.0%



